Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
Chemotherapy that targets microtubular trafficking induces responses in most patients with prostate cancer. One regimen under investigation is the combination of docetaxel and estramustine. We report on 2 patients with androgen-independent disease who received continuous weekly docetaxel and estramustine and who died of irreversible respiratory failure. The clinical, pathologic, and radiographic data support drug toxicity as the likely etiology. Inclusive of these patients, only 17 cases (10 fatal) of acute pulmonary toxicity using docetaxel have been reported, despite its wide use. We recommend that patients receiving weekly docetaxel, with or without estramustine, have frequent treatment breaks and be evaluated with computed tomography of the chest every 8 weeks.
Morris
Michael J
MJ
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Weill Medical College, New York, New York, USA.
Santamauro
Jean
J
Shia
Jinru
J
Schwartz
Lawrence
L
Vander Els
Nicholas
N
Kelly
Kevin
K
Scher
Howard
H
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000077143:Docetaxel; D004961:Estramustine / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011859:Radiography; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D043823:Taxoids
D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D017239:Paclitaxel